Form 4: Mineralys Therapeutics CEO Jon Congleton Sells Shares Under 10b5-1 Trading Plan

Mineralys Therapeutics CEO Jon Congleton executed multiple sales of common stock between June 17 and June 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jon Congleton, CEO of Mineralys Therapeutics, sold shares of common stock between June 17 and June 20, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on January 30, 2024.
• On June 17, 2024, 17,766 shares were sold at a weighted-average price of $12.2544, with prices ranging from $12.0982 to $12.4627.
• On June 18, 2024, 16,607 shares were sold at a weighted-average price of $11.9873, with prices ranging from $11.76 to $12.12.
• On June 20, 2024, 14,940 shares were sold at a weighted-average price of $11.7294, with prices ranging from $11.525 to $12.05.
• Following these transactions, Congleton directly owns 926,958 shares of Mineralys Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. The filing simply reports stock sales under a pre-existing trading plan, which doesn't inherently indicate positive or negative sentiment about the company's future prospects.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, potentially impacting the stock price, although sales under 10b5-1 plans are generally viewed as less concerning.

Industry Context

Sales by executives are a common occurrence, especially under pre-arranged trading plans like Rule 10b5-1, which allows insiders to sell shares without being accused of trading on non-public information. Investors often monitor these filings to understand executive sentiment and potential future stock performance.

Comparison to Industry Standards

• Executive stock sales are a common practice in publicly traded companies, particularly in the pharmaceutical and biotech industries.
• Comparing the size and frequency of these sales to those of executives at similar companies like Chinook Therapeutics (before its acquisition by Novartis) or Travere Therapeutics could provide additional context.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading, aligning with industry best practices.

Stakeholder Impact

• Shareholders may react to the news of the CEO's stock sales, although the existence of a 10b5-1 plan mitigates potential concerns about insider information.

Key Dates